Biosynex SA Overview
Pro stress-test →Biosynex is a French diagnostics company specializing in the design, manufacture, and distribution of rapid diagnostic tests (RDTs) and in-vitro diagnostic (IVD) products. The company serves healthcare professionals, laboratories, and patients globally, with particular focus on tropical diseases, infectious diseases, autoimmunity, and emergency markers. It represents a mid-cap player in the global rapid diagnostics market with diversified product offerings beyond core RDTs.
Strategic Profile
Pro stress-test →Biosynex operates through multiple revenue streams including proprietary diagnostic manufacturing, distribution of third-party diagnostics, R&D services, licensing, and ancillary products (thermometers, blood pressure monitors). The company maintains strong domestic positioning with 56.5% of revenue from France and has developed a comprehensive product portfolio spanning bacteriology, parasitology, mycology, virology, and women's health. Its acquisition-friendly profile (as evidenced by past M&A activity) positions it as a consolidation target in the fragmented European diagnostics space.
Competitive Landscape
Pro stress-test →Biosynex operates in the fragmented rapid diagnostics market alongside larger multinational players (Abbott, Roche, Siemens Healthineers) and specialized competitors (bioMérieux, Chembio Diagnostics). The company's strength lies in niche therapeutic areas (tropical diseases, emergency markers) and European market proximity rather than scale advantages. Recent partnerships with entities like Chembio Diagnostics suggest a hybrid model balancing proprietary products with third-party distribution.
Industry Context
Biosynex SA operates in In-Vitro Diagnostics / Medical Devices.
Key facts
Founded: 1993 · Headquarters: Illkirch-Graffenstaden, France · Employees: 454 · Revenue: €101.2M · Market cap: €141.5M